Company Overview and News

 
AJG / Gallagher (ARTHUR J.) & Co. 8-K (Current Report)

2018-09-13 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AJG

50
Financials And Real Estate Dashboard - Update

2018-08-03 seekingalpha
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages.
BAC BAC JPM CINF CB AJG

 
AJG / Gallagher (ARTHUR J.) & Co. IRANNOTICE

2018-07-27 sec.gov
IRANNOTICE 2850 Golf Road <
AJG

 
AJG / Gallagher (ARTHUR J.) & Co. 10-Q (Quarterly Report)

2018-07-27 sec.gov
10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AJG

4
Arthur J. Gallagher & Co. (AJG) Q2 2018 Results - Earnings Call Transcript

2018-07-27 seekingalpha
Arthur J. Gallagher & Co. (NYSE:AJG) Q2 2018 Earnings Call July 26, 2018 5:15 PM ET
WFCNP DB AJG MS WFC

 
AJG / Gallagher (ARTHUR J.) & Co. 8-K (Current Report)

2018-07-27 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K
AJG

14
AJG / Gallagher (ARTHUR J.) & Co. 8-K (Current Report)

2018-06-13 sec.gov - 1
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AJG

647
Stocks To Watch: Focus On E3, IHOP/b And The World Cup

2018-06-09 seekingalpha - 8
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GOOS GNK AINC CAT TWX DXCM PGR RH AXDX] OPRF AJG NKE SHAK AMZN SCVL AEP MYGN DCI MS VLKAY JBL TTWO CARB TREX FAST INCY PDYPF COMM AXDX NVMI TWC AVT RNG PAP AHBIF MSFT NFG PEG HRB PDYPY NMRK ULTA ADDYY ADP WDAY CASA ADBE GMVHF ATVI CGBD AMTD LII PRTY DIN EXC NEE DIS LUV EA ALGN BUD CMCSA O NEO FDX KFY RGEN EXAS FNSR XEL SIX TGT SCHW T ADPVV ETFC SNE PLAY CAKE CODI

642
Stocks To Watch: Focus On E3, IHopb And The World Cup

2018-06-09 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
GOOS GNK AINC CAT TWX DXCM PGR RH AXDX] OPRF AJG NKE SHAK AMZN SCVL AEP MYGN DCI MS VLKAY JBL TTWO CARB TREX FAST INCY PDYPF COMM AXDX NVMI TWC AVT RNG PAP AHBIF MSFT NFG PEG HRB PDYPY NMRK ULTA ADDYY ADP WDAY CASA ADBE GMVHF ATVI CGBD AMTD LII PRTY DIN EXC NEE DIS LUV EA ALGN BUD CMCSA O NEO FDX KFY RGEN EXAS FNSR XEL SIX TGT SCHW T ADPVV ETFC SNE PLAY CAKE CODI

13
AJG / Gallagher (ARTHUR J.) & Co. 8-K (Current Report)

2018-05-21 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AJG

14
AJG / Gallagher (ARTHUR J.) & Co. FORM 10-Q (Quarterly Report)

2018-05-07 sec.gov - 1
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
AJG

13
AJG / Gallagher (ARTHUR J.) & Co. IRANNOTICE

2018-05-07 sec.gov
IRANNOTICE 2850 Golf Road
AJG

13
Arthur J. Gallagher & Co. (AJG) Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Arthur J. Gallagher & Co. (NYSE:AJG) Q1 2018 Earnings Call May 1, 2018 5:15 PM ET
AJG

15
AJG / Gallagher (ARTHUR J.) & Co. 8-K (Current Report)

2018-05-01 sec.gov - 2
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K
AJG

13
AJG / Gallagher (ARTHUR J.) & Co. 8-K (Current Report)

2018-04-10 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AJG

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

5h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

CUSIP: 363576109